TIRZEPATIDE
Tirzepatide + B12 is a once-weekly injectable medication formulation that targets both GLP-1 and GIP receptors to support blood sugar regulation, enhance insulin sensitivity, and promote weight loss. It helps reduce appetite, slow gastric emptying, and improve metabolic flexibility, making it one of the most effective tools for long-term fat loss and metabolic health support. Available compounded with either B12 or Glycine, your provider will confirm the right option for you as part of your intake. Formulation, strength, and dosing are determined based on your provider's assessment.
START NOW- MECHANISM OF ACTION
- Tirzepatide activates the GLP-1 and GIP pathways to regulate glucose levels, suppress appetite, delay gastric emptying, and stimulate insulin secretion. The dual action increases energy efficiency and reduces fat storage while promoting satiety and metabolic reprogramming.
- Increased weight loss and reduced visceral fat
- Improved blood glucose and insulin sensitivity
- Appetite suppression and reduced food cravings
- Cardiometabolic protection and inflammation reduction
- Improved energy, satiety, and long-term metabolic regulation
- TOTAL CONTENT
- Dose dependent, determined by your provider
- CONCENTRATION
- Varies by prescribed dose and formulation
- VIAL SIZE
- 2ml
- SUPPLY
- 4 week supply
- STORAGE
- Refrigerate at 36–46°F (2–8°C). Do not freeze.
- Mild injection site redness or discomfort
- Nausea, constipation, or diarrhea (common early)
- Decreased appetite or food aversion
- Vomiting or delayed gastric emptying (rare)
- Active cancer
- Pregnancy or breastfeeding
- Known hypersensitivity to any medication components
This therapy should be used under the guidance of a healthcare provider. If you experience any of the following, discontinue use and contact us immediately:
- Severe swelling or injection site reaction
- Fever >100.4°F (38°C)
- Fatigue that worsens over time
- Signs of pancreatitis, gallbladder pain, or severe nausea
- Shortness of breath, chest tightness, or facial swelling
- Persistent GI symptoms prevent eating or hydration








